ToolGen Inc.
ToolGen Incorporated, a biotechnology company, focuses on the development of genome editing technology in South Korea. The company develops clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene scissors for gene editing in eukaryotic cells. It is involved in patent monetization, treatment, and seed businesses. ToolGen Incorporated was founded in 1999 and is based in Seoul, … Read more
ToolGen Inc. (199800) - Net Assets
Latest net assets as of September 2025: ₩53.51 Billion KRW
Based on the latest financial reports, ToolGen Inc. (199800) has net assets worth ₩53.51 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩68.38 Billion) and total liabilities (₩14.88 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩53.51 Billion |
| % of Total Assets | 78.25% |
| Annual Growth Rate | 16.79% |
| 5-Year Change | 95.5% |
| 10-Year Change | N/A |
| Growth Volatility | 91.07 |
ToolGen Inc. - Net Assets Trend (2016–2024)
This chart illustrates how ToolGen Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ToolGen Inc. (2016–2024)
The table below shows the annual net assets of ToolGen Inc. from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩58.44 Billion | +94.17% |
| 2023-12-31 | ₩30.09 Billion | -57.29% |
| 2022-12-31 | ₩70.47 Billion | -16.77% |
| 2021-12-31 | ₩84.66 Billion | +183.24% |
| 2020-12-31 | ₩29.89 Billion | +11.66% |
| 2019-12-31 | ₩26.77 Billion | -27.62% |
| 2018-12-31 | ₩36.99 Billion | +184.78% |
| 2017-12-31 | ₩12.99 Billion | -23.08% |
| 2016-12-31 | ₩16.89 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ToolGen Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11574165347000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩4.27 Billion | 7.31% |
| Other Components | ₩183.58 Billion | 314.15% |
| Total Equity | ₩58.44 Billion | 100.00% |
ToolGen Inc. Competitors by Market Cap
The table below lists competitors of ToolGen Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Norwood Financial Corp
NASDAQ:NWFL
|
$231.17 Million |
|
Nanjing Port Co Ltd
SHE:002040
|
$231.18 Million |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
$231.22 Million |
|
Guangzheng Group Co Ltd
SHE:002524
|
$231.22 Million |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
$231.15 Million |
|
Appen Ltd
AU:APX
|
$231.12 Million |
|
Tredegar Corporation
NYSE:TG
|
$231.12 Million |
|
Evolent Health Inc
NYSE:EVH
|
$231.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ToolGen Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,094,560,630 to 58,435,847,290, a change of 28,341,286,660 (94.2%).
- Net income of 6,231,842,140 contributed positively to equity growth.
- Share repurchases of 21,795,848,540 reduced equity.
- New share issuances of 21,795,848,530 increased equity.
- Other factors increased equity by 22,109,444,530.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩6.23 Billion | +10.66% |
| Share Repurchases | ₩21.80 Billion | -37.3% |
| Share Issuances | ₩21.80 Billion | +37.3% |
| Other Changes | ₩22.11 Billion | +37.84% |
| Total Change | ₩- | 94.17% |
Book Value vs Market Value Analysis
This analysis compares ToolGen Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.77x to 7.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2922.55 | ₩49000.00 | x |
| 2017-12-31 | ₩2237.86 | ₩49000.00 | x |
| 2018-12-31 | ₩5775.16 | ₩49000.00 | x |
| 2019-12-31 | ₩4109.73 | ₩49000.00 | x |
| 2020-12-31 | ₩4447.95 | ₩49000.00 | x |
| 2021-12-31 | ₩10785.24 | ₩49000.00 | x |
| 2022-12-31 | ₩8939.83 | ₩49000.00 | x |
| 2023-12-31 | ₩3801.37 | ₩49000.00 | x |
| 2024-12-31 | ₩6837.30 | ₩49000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ToolGen Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.66%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 699.45%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.29x
- Recent ROE (10.66%) is above the historical average (-40.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -17.87% | -195.85% | 0.08x | 1.08x | ₩-4.71 Billion |
| 2017 | -33.44% | -130.09% | 0.22x | 1.17x | ₩-5.64 Billion |
| 2018 | -21.78% | -696.46% | 0.03x | 1.05x | ₩-11.76 Billion |
| 2019 | -58.95% | -1402.71% | 0.04x | 1.12x | ₩-18.46 Billion |
| 2020 | -49.79% | -2086.95% | 0.02x | 1.08x | ₩-17.87 Billion |
| 2021 | -24.44% | -1295.49% | 0.02x | 1.03x | ₩-29.16 Billion |
| 2022 | -25.79% | -2444.93% | 0.01x | 1.07x | ₩-25.22 Billion |
| 2023 | -140.69% | -3837.21% | 0.01x | 3.11x | ₩-45.35 Billion |
| 2024 | 10.66% | 699.45% | 0.01x | 1.29x | ₩388.26 Million |
Industry Comparison
This section compares ToolGen Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $259,224,420,269
- Average return on equity (ROE) among peers: -0.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ToolGen Inc. (199800) | ₩53.51 Billion | -17.87% | 0.28x | $231.16 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |